Can a genetically modified oral vaccine beat cholera?
NCT ID NCT07107516
First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time
Summary
This trial tests a new oral cholera vaccine called PanChol in healthy adults aged 18 to 55 in Zambia. The vaccine is designed to be safer and more effective than current options. Researchers will monitor participants for side effects and measure their immune response after vaccination.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a novel live attenuated oral cholera vaccine called PanChol
- What this could lead to
- If successful, PanChol could offer a more effective way to prevent cholera, a severe diarrheal disease that can be fatal within hours.
- What could go wrong
- This is an early Phase 1 trial with only 32 participants, so the vaccine may not prove safe or effective in larger studies. Side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHOLERA VACCINATION REACTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CIDRZ Matero clinical reseach site
RECRUITINGLusaka, Lusaka Province, 10101, Zambia
More trials for these conditions
Other studies related to the condition(s) this trial covers.